Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RX-10100 (Serdaxin) in Major Depressive Disorder
NCT00839176Phase 2Completed
- Sponsor
- Rexahn Pharmaceuticals
- Start
- Jan 2009
- Primary completion
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of clavulanic acid in major depressive disorder (MDD), sponsored by Rexahn Pharmaceuticals. Started Jan 2009; status: completed.
02
Drugs
clavulanic acid
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00839176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00839176.